Sugi Predict

Sugi Predict / Compounds / SCHEMBL160615

SCHEMBL160615

SCHEMBL160615

COC(=O)c1sccc1CN

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.54
▸ MEN1 O00255 4/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ NPC1 O15118 1/20 0.49
▸ ALDH1A1 P00352 4/20 0.47
▸ KDM4E B2RXH2 3/20 0.47
▸ POLB P06746 1/20 0.47
▸ HPGD P15428 2/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ MAPK10 P53779 5/20 0.46
▸ NPSR1 Q6W5P4 3/20 0.46
▸ PRNP P04156 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.46
▸ MAPK8 P45983 3/20 0.46
▸ MAPK9 P45984 3/20 0.46
▸ GAA P10253 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ LOXL2 Q9Y4K0 1/20 0.44
▸ HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8630249 0.85 KMT2A (0.62) KMT2AMEN1CYP1A2NPC1ALDH1A1
SCHEMBL4683311 0.84 KMT2A (0.56) KMT2AMEN1CYP1A2NPC1ALDH1A1
SCHEMBL23142270 0.83 KMT2A (0.49) KMT2AMEN1CYP1A2NPC1ALDH1A1
SCHEMBL5187967 0.82 KMT2A (0.54) KMT2AMEN1CYP1A2NPC1ALDH1A1
SCHEMBL158675 0.82 KMT2A (0.54) KMT2AMEN1CYP1A2NPC1ALDH1A1
SCHEMBL4730278 0.81 KMT2A (0.36) KMT2AMEN1CYP1A2NPC1ALDH1A1
SCHEMBL8636706 0.81 KMT2A (0.53) KMT2AMEN1CYP1A2NPC1ALDH1A1
SCHEMBL6625082 0.81 KMT2A (0.57) KMT2AMEN1CYP1A2NPC1ALDH1A1
SCHEMBL8634771 0.79 KMT2A (0.51) KMT2AMEN1CYP1A2NPC1ALDH1A1
SCHEMBL14364307 0.79 KMT2A (0.51) KMT2AMEN1CYP1A2NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240092799-A1 MNK INHIBITORS HEPAGENE THERAPEUTICS HK LTD (CN) 2024-03-21 — — US disclosed
WO-2024046420-A1 FUSED BICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE 江苏恒瑞医药股份有限公司 2024-03-07 — — WO disclosed
EP-3735404-B1 ASK1 INHIBITOR COMPOUNDS AND USES THEREOF SEAL ROCK THERAPEUTICS INC (US) 2023-11-29 — — EP disclosed
CN-116490505-A MNK inhibitors 和博医药有限公司 2023-07-25 — — CN disclosed
WO-2023134656-A1 PEPTIDYL NITRILE COMPOUND AND USE THEREOF 上海壹典医药科技开发有限公司 2023-07-20 — — WO disclosed
EP-4200296-A1 MNK INHIBITORS Hepagene Therapeutics (HK) Limited (HK) 2023-06-28 — — EP disclosed
US-11572356-B2 Biaryl inhibitors of Bruton's tyrosine kinase BIOGEN MA INC. (US) 2023-02-07 — — US disclosed
US-11572356-B2 Biaryl inhibitors of Bruton's tyrosine kinase BIOGEN MA INC. (US) 2023-02-07 — — US disclosed
US-20220332705-A1 BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE BIOGEN MA INC. 2022-10-20 — — US disclosed
CN-109096274-B Biaryl compounds useful in the treatment of human oncological, neurological and immunological diseases 比奥根MA公司 2022-07-01 — — CN disclosed
US-7893058-B2 Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases JANSSEN PHARMACEUTICA NV (BE) 2011-02-22 — — US disclosed
US-7893058-B2 Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases JANSSEN PHARMACEUTICA NV (BE) 2011-02-22 — — US disclosed
EP-1942890-A4 CHEMOKINE RECEPTOR BINDING COMPOUNDS GENZYME CORP (US) 2009-08-26 — — EP disclosed
EP-1942890-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2008-07-16 — — EP disclosed
US-20070281943-A1 Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-06 — — US disclosed
US-20070281943-A1 Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-06 — — US disclosed
US-20070281943-A1 Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-06 — — US disclosed
WO-2007131991-A1 IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N.V. (BE) 2007-11-22 — — WO disclosed
WO-2006138350-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2006-12-28 — — WO disclosed
US-4325963-A ANTIDIABETIC AGENT HOECHST AKTIENGESELLSCHAFT (DE) 1982-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572356-B2 Biaryl inhibitors of Bruton's tyrosine kinase ABL1, BTK, LYN KMT2A 1470/4885MEN1 4232/4885CYP1A2 2341/4885
US-20240092799-A1 MNK INHIBITORS MKNK1, MATK, NEK1 KMT2A 443/4885MEN1 713/4885CYP1A2 4615/4885
US-20220332705-A1 BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE ABL1, BTK, LYN KMT2A 1470/4885MEN1 4232/4885CYP1A2 2341/4885
US-20070281943-A1 Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases IKZF3, IRAK2, IRAK1 KMT2A 4278/4885MEN1 4569/4885CYP1A2 1010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.